This study shows that mutations in KRAS, TP53 and CCND2, along with the VAF detected by liquid biopsy testing at diagnosis could be recognized as prognostic biomarkers in patients with advanced pancreatic cancer. The gene discussed is CCND2; the disease is familial pancreatic carcinoma.